Back to top
more

Iovance Biotherapeutics (IOVA)

(Delayed Data from NSDQ)

$11.78 USD

11.78
4,388,023

-0.25 (-2.08%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $11.90 +0.12 (1.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IOVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Iovance Biotherapeutics, Inc. [IOVA]

Reports for Purchase

Showing records 141 - 160 ( 180 total )

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 141

02/26/2020

Company Report

Pages: 9

2020 Outlook: Data, BLAs and Manufacturing, Oh My; Maybe Even a Takeout? Target Upped to $36

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 142

01/16/2020

Company Report

Pages: 7

Busy Week for Iovance Team as BLAs Approach This Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 143

11/21/2019

Company Report

Pages: 5

Cohort 2 Data in Checkpoint Primary Refractory Population Further Solidifies Our Thesis

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 144

11/11/2019

Company Report

Pages: 7

3Q19 Activity and Safety-Centric Validation In-House; Awaiting Mature Data in 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 145

11/05/2019

Company Report

Pages: 6

3Q19 Results; Important SITC Update This Weekend; BLAs on Track by YE20; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 146

09/26/2019

Company Report

Pages: 7

Investor Breakfast Highlights Full Steam Ahead for All Programs; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 147

08/02/2019

Company Report

Pages: 7

2Q19 Results; Building on Novel TIL Opportunities; BLA Filings for Both LN-144 and LN-145 Expected by YE20

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 148

07/02/2019

Daily Note

Pages: 4

Data, FDA Visibility, and Another Targeted BLA; Priceless

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 149

06/24/2019

Industry Report

Pages: 19

Our Thoughts Post CAR-T and the Rise of the Cellicon Valley Summit

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 150

06/03/2019

Company Report

Pages: 10

TILs Continue to Shine at ASCO; Target Increased to $32

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 151

05/29/2019

Daily Note

Pages: 4

Further Preparations for Commercial Success; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 152

05/23/2019

Daily Note

Pages: 6

Shocker (Not), LN-145 Granted Breakthrough Therapy Designation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 153

05/16/2019

Daily Note

Pages: 7

ASCO Melanoma Abstract Data Continue to Solidify Confidence in Pivotal Study

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 154

05/08/2019

Company Report

Pages: 6

1Q19 Results; Upcoming Inflection Points at ASCO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 155

04/03/2019

Daily Note

Pages: 4

Important Chess Moves to Head Regulatory Agencies off at the Pass

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 156

04/02/2019

Daily Note

Pages: 3

Iovance Officially Goes Pivotal; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 157

04/01/2019

Daily Note

Pages: 4

TIL Persistence in Patients and Continued Case for Polyclonal Approach; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 158

02/28/2019

Company Report

Pages: 7

2018 results; Building the Foundation for TILs in Solid Tumors; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 159

11/12/2018

Company Report

Pages: 11

SITC Updates Continue to Solidify Thesis

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 160

10/12/2018

Company Report

Pages: 6

What We''ve All Been Waiting For, Plus RMAT and a Chunk of Cash; Price Target Raised to $26

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party